The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFβ receptor involved in tumor angiogenesis.
L. W. Goff
No relevant relationships to disclose
R. B. Cohen
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
J. Berlin
Research Funding - Pfizer
C. Noberasco
No relevant relationships to disclose
H. Borghaei
No relevant relationships to disclose
C. Gallo-Stampino
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
E. Wang
Employment or Leadership Position - Pfizer
D. Hu Lowe
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
W. J. Levin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
F. G. De Braud
Honoraria - Pfizer
Research Funding - Pfizer